8.1.5: Other Antineoplastic Drugs

Part of chapter 8 Malignant Disease & Immunosuppression, section 8.1 Cytotoxic Drugs


High-level prescribing trends for Other Antineoplastic Drugs (BNF section 8.1.5) across all GP practices in NHS England for the last five years. You can explore prescribing trends for this section by CCG, or learn more about this site.

No prescriptions found.

Do you need help with your analysis? We can provide custom extracts from our prescribing data for free. to find out more.

Chemicals

Axitinib (0801050BJ)
Bexarotene (0801050AB)
Carboplatin (0801050F0)
Celecoxib (0801050AY)
Dasatinib (0801050AN)
Docetaxel (0801050D0)
Erlotinib (0801050AE)
Everolimus (0801050AX)
Gefitinib (0801050AW)
Hydroxycarbamide (0801050P0)
Ibrutinib (0801050BS)
Imatinib Mesilate (0801050AA)
Lapatinib (0801050AT)
Mitotane (0801050R0)
Nilotinib (0801050AS)
Nintedanib (0801050BT)
Osimertinib (0801050CG)
Paclitaxel (0801050V0)
Pazopanib (0801050AZ)
Pipobroman (0801050BH)
Ponatinib (0801050BQ)
Procarbazine Hydrochloride (0801050U0)
Ruxolitinib (0801050BI)
Sorafenib (0801050AJ)
Sunitinib (0801050AM)
Temozolomide (0801050Y0)
Topotecan (0801050AF)
Trametinib (0801050CH)
Trastuzumab (0801050AD)
Tretinoin (0801050X0)
Vandetanib (0801050BG)